Relationships among symptoms, bother, and treatment satisfaction in overactive bladder patients

被引:30
作者
Michel, Martin C.
Oelke, Matthias
Goepel, Mark
Beck, Elmar
Burkart, Martin
机构
[1] Univ Amsterdam, Acad Med Ctr, Afd Farmacol & Farmacotherapie, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1105 AZ Amsterdam, Netherlands
[3] Klinikum Niderberg, Dept Urol, Velbert, Germany
[4] Anfomed Gmbh, Erlangen, Germany
[5] Pfizer Pharma GmbH, Karlsruhe, Germany
关键词
bother; factor analysis; overactive bladder; symptom scales; tolterodine; treatment satisfaction;
D O I
10.1002/nau.20367
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aims: We have studied the association between various symptoms, bother, and patient treatment satisfaction in overactive bladder (OAB). Methods: Episodes of urgency, incontinence, daytime frequency and nocturia and responses to the patient perception of bladder condition scale, the urgency perception scale, and visual analog scales of limitations in daily life and of treatment satisfaction were evaluated in 3,824 OAB patients at baseline and during 9 months treatment with tolterodine ER (4 mg q.d.) in an open-label, observational study. Relationships amongst number of symptoms/24 hr and scales were explored. Treatment satisfaction was correlated with improvements in symptoms and scales. Results: At baseline, the number of episodes of the four OAB symptoms correlated only poorly with each other and with the two bother-related scales, while the two scales assessing bother correlated much stronger with each other. Factor analysis identified four components which described "bother," "incontinence," "urgency/frequency," and "nocturia" and in combination explained 81.9% of the total variance. The component "bother" had the strongest individual effect accounting for 42.1% of the total variance. While improvements of symptoms and bother were seen with tolterodine treatment, patient treatment satisfaction correlated strongest with improvements of the two bother-related scales. Conclusions: We conclude that the counting of episodes of OAB symptoms only insufficiently describes the afflicted patients. Patient bother is the strongest individual component but only poorly explained by episodes of the four symptoms defining OAB. Alterations of bother may better reflect patient-relevant outcomes in OAB treatment than alterations in the number of symptom episodes.
引用
收藏
页码:190 / 195
页数:6
相关论文
共 24 条
[1]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[2]   Filling and voiding symptoms in the American Urological Association symptom index: The value of their distinction in a Veterans Affairs randomized trial of medical therapy in men with a clinical diagnosis of benign prostatic hyperplasia [J].
Barry, MJ ;
Williford, WO ;
Fowler, FJ ;
Jones, KM ;
Lepor, H .
JOURNAL OF UROLOGY, 2000, 164 (05) :1559-1564
[3]  
BERNER MM, 2006, J SEX MED S3, V3, P201
[4]   Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment [J].
Brady, CM ;
Apostolidis, AN ;
Harper, M ;
Yiangou, Y ;
Beckett, A ;
Jacques, TS ;
Freeman, A ;
Scaravilli, F ;
Fowler, CJ ;
Anand, P .
BJU INTERNATIONAL, 2004, 93 (06) :770-776
[5]   A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: Data from a randomized controlled trial of surgery for women with stress incontinence [J].
Brookes, ST ;
Donovan, JL ;
Wright, M ;
Jackson, S ;
Abrams, P .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2004, 191 (01) :73-82
[6]   Increased warning time with darifenacin: A new concept in the management of urinary urgency [J].
Cardozo, L ;
Dixon, A .
JOURNAL OF UROLOGY, 2005, 173 (04) :1214-1218
[7]   Validation of the Urgency Perception Scale [J].
Cardozo, L ;
Coyne, KS ;
Versi, E .
BJU INTERNATIONAL, 2005, 95 (04) :591-596
[8]   The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects [J].
Chapple, CR ;
Artibani, W ;
Cardozo, LD ;
Castro-Diaz, D ;
Craggs, M ;
Haab, F ;
Khullar, V ;
Versi, E .
BJU INTERNATIONAL, 2005, 95 (03) :335-340
[9]   Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: The OAB-q [J].
Coyne, K ;
Revicki, D ;
Hunt, T ;
Corey, R ;
Stewart, W ;
Bentkover, J ;
Kurth, H ;
Abrams, P .
QUALITY OF LIFE RESEARCH, 2002, 11 (06) :563-574
[10]   Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine [J].
Freeman, R ;
Hill, S ;
Millard, R ;
Slack, M ;
Sutherst, J .
OBSTETRICS AND GYNECOLOGY, 2003, 102 (03) :605-611